Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 3:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: darbepoetin alfa Clear all
Completed Phase 3 Interventional Results available

A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia

NCT00090753
View directory record Official record
Conditions
Anemia
Interventions
Methoxy Polyethylene Glycol-Epoetin Beta, Epoetin alfa, Epoetin beta, Darbepoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
83
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 22, 2026, 3:24 PM EDT
Completed Phase 3 Interventional Results available

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

NCT04313153
View directory record Official record
Conditions
Anemia
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Chula Vista, California • Granada Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 22, 2026, 3:24 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

NCT00598442
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Darbepoetin alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
42
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Sep 22, 2026, 3:24 PM EDT
Completed Phase 3 Interventional Results available

RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

NCT00358215
View directory record Official record
Conditions
Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction, Congestive Heart Failure
Interventions
Darbepoetin alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
2,278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
254
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 195 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 22, 2026, 3:24 PM EDT
Completed Phase 3 Interventional Results available

Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants

NCT04484857
View directory record Official record
Conditions
Anemia Associated With End Stage Renal Disease
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Anchorage, Alaska • Pine Bluff, Arkansas • Cerritos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 22, 2026, 3:24 PM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

NCT02879305
View directory record Official record
Conditions
Anaemia, Aspergillosis, Allergic Bronchopulmonary
Interventions
Daprodustat, rhEPO, Placebo, Iron therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
126
States / cities
Huntsville, Alabama • Pine Bluff, Arkansas • Anaheim, California + 103 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 22, 2026, 3:24 PM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma

NCT00058422
View directory record Official record
Conditions
Lymphoma
Interventions
darbepoetin alfa, filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan
Biological · Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 22, 2026, 3:24 PM EDT
Completed Phase 4 Interventional

A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer

NCT00153868
View directory record Official record
Conditions
Anemia, Cancer
Interventions
darbepoetin alfa
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Sep 22, 2026, 3:24 PM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

NCT03242967
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Northridge, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Sep 22, 2026, 3:24 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

NCT00520468
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Erythropoietin, Cyclosporin A, G-CSF, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 22, 2026, 3:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Project CARE: CAncer Risk Evaluation

NCT07130487
View directory record Official record
Conditions
Primary Care
Interventions
Relational Agent ( RA) Alex
Behavioral
Lead sponsor
Anita Y. Kinney, PhD, RN
Other
Eligibility
18 Years to 70 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 22, 2026, 3:24 PM EDT
Completed Phase 2 Interventional Results available

The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial

NCT00647998
View directory record Official record
Conditions
Spinal Ischemia, Stroke, Neuroprotection
Interventions
Darbepoetin alfa, Standard care
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 22, 2026, 3:24 PM EDT
Completed Phase 2 Interventional

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00077311
View directory record Official record
Conditions
Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
Interventions
darbepoetin alfa, pegfilgrastim, cisplatin, docetaxel, BNP7787
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
64
States / cities
Mountain View, California • Lewes, Delaware • Newark, Delaware + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Sep 22, 2026, 3:24 PM EDT
Terminated Phase 2 Interventional Results available

Mechanisms of EPO-induced Hypertension

NCT03810911
View directory record Official record
Conditions
Chronic Kidney Disease, Blood Pressure, Anemia
Interventions
Darbepoetin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 22, 2026, 3:24 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

NCT04798339
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Canakinumab Injection, Darbepoetin Alfa
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 22, 2026, 3:24 PM EDT
Completed Phase 2 Interventional Results available

Mild Encephalopathy in the Newborn Treated With Darbepoetin

NCT03071861
View directory record Official record
Conditions
Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy Mild
Interventions
Darbepoetin Alfa, Normal Saline
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
1 Hour to 24 Hours
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 22, 2026, 3:24 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Luspatercept + Darbepoetin in MDS

NCT07096297
View directory record Official record
Conditions
MDS (Myelodysplastic Syndrome)
Interventions
Luspatercept, Darbeopoetin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
4
States / cities
New Haven, Connecticut • Chicago, Illinois • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 22, 2026, 3:24 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Will Radiation/Chemotherapy Treatment of Cervical Cancer Work Better With Medication That May Improve Anemia?

NCT00039884
View directory record Official record
Conditions
Anemia, Cervix Neoplasms
Interventions
NESP - Novel Erythropoiesis Stimulating Protein
Drug
Lead sponsor
Mirhashemi, Ramin, M.D.
Individual
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 22, 2026, 3:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

NCT02892149
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
127
States / cities
Huntsville, Alabama • Mesa, Arizona • Pine Bluff, Arkansas + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Sep 22, 2026, 3:24 PM EDT
Terminated Phase 2 Interventional Results available

Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes

NCT00398047
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
Azacitadine and Hematopoietic Growth Factors
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 22, 2026, 3:24 PM EDT
Terminated Phase 2 Interventional Results available

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

NCT00386152
View directory record Official record
Conditions
Neoplasms, Anemia, Cancer
Interventions
epoetin alfa, darbepoetin alfa
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
76
States / cities
Glendale, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 22, 2026, 3:24 PM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

NCT00598273
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Darbepoetin alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
68
States / cities
Montgomery, Alabama • Tempe, Arizona • Hot Springs, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Sep 22, 2026, 3:24 PM EDT
Completed Phase 3 Interventional Results available

Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer

NCT00661999
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
darbepoetin alfa, ferrous sulfate, sodium ferric gluconate complex in sucrose, placebo
Biological · Dietary Supplement · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2011 · Synced Sep 22, 2026, 3:24 PM EDT
Completed Not applicable Interventional

Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation

NCT00355407
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Darbepoetin alfa
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Sep 22, 2026, 3:24 PM EDT